利用血浆游离RNA特征无创预测子痫前期
本研究采用多聚腺苷酸化连接介导测序法,分析715例健康妊娠和202例子痫前期妊娠在症状出现前的血浆游离RNA特征,并利用机器学习构建早产型子痫前期和早发型子痫前期预测分类器。早产型模型在独立验证队列中曲线下面积81%、阳性预测值68%;早发型模型在外部验证队列中曲线下面积88%、阳性预测值73%。
要点
- 早产型子痫前期预测模型在独立验证队列中曲线下面积81%、阳性预测值68%。
- 早发型子痫前期预测模型在外部验证队列中曲线下面积88%、阳性预测值73%。
- 基于13种游离RNA特征和2项临床特征(体外受精和平均动脉压)分别构建两个分类器。
核心结论
- 本研究呈现了子痫前期不同RNA生物型的综合转录组图谱,并开发了两个在症状出现前预测早产型子痫前期和早发型子痫前期具有重要临床意义的先进分类器。
- 信使RNA、微小RNA和长链非编码RNA可同时作为子痫前期的潜在生物标志物,有望在未来用于子痫前期的预防。
- 异常的游离信使RNA、微小RNA和长链非编码RNA分子变化可能有助于阐明子痫前期的致病决定因素,并为有效减少妊娠并发症和胎儿发病率开辟新的治疗窗口。
研究设计与样本
- 本研究为队列研究,采用名为多聚腺苷酸化连接介导测序的新型游离RNA测序方法,研究715例健康妊娠和202例子痫前期妊娠在症状出现前的血浆游离RNA特征。
- 研究探索了健康与子痫前期样本之间血浆中不同RNA生物型丰度的差异,并使用机器学习方法构建早产型子痫前期和早发型子痫前期预测分类器。
- 研究使用外部和内部验证队列验证分类器的性能,并评估曲线下面积和阳性预测值。
主要发现
- 在健康母亲和症状出现前的早产型子痫前期母亲中检测到77个差异表达基因,包括信使RNA(44%)和微小RNA(26%),这些基因可将早产型子痫前期参与者与健康样本区分开,并在子痫前期生理学中发挥关键功能作用。
- 基于13种游离RNA特征和2项临床特征(体外受精和平均动脉压)分别开发了两个用于在诊断前预测早产型子痫前期和早发型子痫前期的分类器。
- 两个分类器与现有方法相比均表现出增强的性能。
- 早产型子痫前期预测模型在独立验证队列(早产型,n=46;对照,n=151)中达到81%的曲线下面积和68%的阳性预测值。
- 早发型子痫前期预测模型在外部验证队列(早发型子痫前期,n=28;对照,n=234)中曲线下面积为88%,阳性预测值为73%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preeclampsia, especially preterm preeclampsia and early-onset preeclampsia, is a life-threating pregnancy disorder, and the heterogeneity and complexity of preeclampsia make it difficult to predict risk and to develop treatments. Plasma cell-free RNA carries unique information from human tissue and may be useful for noninvasive monitoring of maternal, placental, and fetal dynamics during pregnancy. OBJECTIVE: This study aimed to investigate various RNA biotypes associated with preeclampsia in plasma and to develop classifiers to predict preterm preeclampsia and early-onset preeclampsia before diagnosis. STUDY DESIGN: We performed a novel, cell-free RNA sequencing method termed polyadenylation ligation-mediated sequencing to investigate the cell-free RNA characteristics of 715 healthy pregnancies and 202 pregnancies affected by preeclampsia before symptom onset. We explored differences in the abundance of different RNA biotypes in plasma between healthy and preeclampsia samples and built preterm preeclampsia and early-onset preeclampsia prediction classifiers using machine learning methods. Furthermore, we validated the performance of the classifiers using the external and internal validation cohorts and assessed the area under the curve and positive predictive value. RESULTS: We detected 77 genes, including messenger RNA (44%) and microRNA (26%), that were differentially expressed in healthy mothers and mothers with preterm preeclampsia before symptom onset, which could separate participants with preterm preeclampsia from healthy samples and that played critical functional roles in preeclampsia physiology. We developed 2 classifiers for predicting preterm preeclampsia and early-onset preeclampsia before diagnosis based on 13 cell-free RNA signatures and 2 clinical features (in vitro fertilization and mean arterial pressure), respectively. Notably, both classifiers showed enhanced performance when compared with the existing methods. The preterm preeclampsia prediction model achieved 81% area under the curve and 68% positive predictive value in an independent validation cohort (preterm, n=46; control, n=151); the early-onset preeclampsia prediction model had an area under the curve of 88% and a positive predictive value of 73% in an external validation cohort (early-onset preeclampsia, n=28; control, n=234). Furthermore, we demonstrated that downregulation of microRNAs may play vital roles in preeclampsia through the upregulation of preeclampsia-relevant target genes. CONCLUSION: In this cohort study, a comprehensive transcriptomic landscape of different RNA biotypes in preeclampsia was presented and 2 advanced classifiers with substantial clinical importance for preterm preeclampsia and early-onset preeclampsia prediction before symptom onset were developed. We demonstrated that messenger RNA, microRNA, and long noncoding RNA can simultaneously serve as potential biomarkers of preeclampsia, holding the promise of prevention of preeclampsia in the future. Abnormal cell-free messenger RNA, microRNA, and long noncoding RNA molecular changes may help to elucidate the pathogenic determinants of preeclampsia and open new therapeutic windows to effectively reduce pregnancy complications and fetal morbidity.
引用
- Zhou S, Li J, Yang W, et al. Noninvasive preeclampsia prediction using plasma cell-free RNA signatures. Am J Obstet Gynecol. 2023. PMID: 37211139. doi:10.1016/j.ajog.2023.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。